Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10620-022-07448-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gastrointestinal Perforations Associated With JAK Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
United European Gastroenterol J
December 2024
The Sheba Talpiot Medical Leadership Program, Sheba Medical Center, Ramat-Gan, Israel.
Background: Gastrointestinal perforations have been reported in a small number of rheumatoid arthritis (RA) patients treated with Janus kinase (JAK) inhibitors in clinical trials. However, large-scale postmarketing data repositories are needed to further investigate this potentially rare but serious adverse event.
Methods: A retrospective, pharmacovigilance study of the FDA adverse event reporting system (July 2014 to September 2023) assessing the reporting of gastrointestinal perforations following JAK inhibitors compared to biological disease-modifying antirheumatic drugs (bDMARDs) in RA patients.
Effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthritis: results from the United States CorEvitas Rheumatoid Arthritis Registry.
Clin Rheumatol
December 2024
Pfizer Inc, Collegeville, PA, USA.
Objectives: To compare effectiveness of tofacitinib versus tumor necrosis factor inhibitors (TNFi), and across tofacitinib lines of therapy, in patients with rheumatoid arthritis (RA), using US CorEvitas RA Registry data.
Methods: Analysis included patients with RA initiating tofacitinib or TNFi with a 12-month follow-up visit between November 2012-February 2021. Primary (Clinical Disease Activity Index-defined low disease activity [CDAI-LDA: CDAI ≤ 10]) and secondary (clinical/disease activity/patient-reported) effectiveness outcomes were assessed at month 12.
Small Molecules, Big Results: How JAK Inhibitors Have Transformed the Treatment of Patients with IBD.
Dig Dis Sci
December 2024
Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Small molecule Janus kinase (JAK) inhibitors have revolutionized the management of ulcerative colitis (UC) and Crohn's disease (CD) through their low immunogenicity, safety, and consistent pharmacologic response that are superior to existing therapeutic options. In this perspective, we highlight existing evidence supporting the use of currently approved JAK inhibitors (upadacitinib, tofacitinib, and filgotinib) for UC or CD, additionally emphasizing the evidence for their use in related autoimmune conditions such as rheumatoid arthritis and spondyloarthropathies. Our perspective concludes with a review of the existing comparative effectiveness literature, which positions JAK inhibitors, particularly upadacitinib, favorably compared with other biologic therapies.
View Article and Find Full Text PDFEfficacy and Safety of Janus Kinase-Inhibitors in Ulcerative Colitis.
J Clin Med
November 2024
Gastroenterology Unit, Department of Systems Medicine, University "Tor Vergata" of Rome, 00133 Rome, Italy.
Janus kinase-inhibitors (JAK-i) have recently been approved for treating patients with Ulcerative Colitis (); therefore, further information is needed, particularly regarding efficacy and safety. To provide a comprehensive review regarding the efficacy and safety of currently available JAK-i in UC. The PubMed and Scopus databases were considered, searching for 'JAK', 'JAK-inhibitor', 'Janus Kinases', 'Tofacitinib', 'Filgotinib', 'Upadacitinib', individually or in combination with 'IBD', 'Ulcerative Colitis', 'safety', 'efficacy', 'study' and 'trial'.
View Article and Find Full Text PDFContemplating Novel W/O Emulsion Based Gel for Anti-Psoriatic Activity of Tofacitinib in Imiquimod-Induced Balb/C Mice Model.
AAPS PharmSciTech
December 2024
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, 500037, India.
Article Synopsis
- Tyrosine kinase inhibitors like tofacitinib (TCB) are effective in treating psoriasis, and this study aims to enhance TCB's effectiveness while minimizing side effects through a new topical emulgel formulation.
- The emulgel was created by combining TCB with various ingredients, resulting in a formulation with ideal viscosity, firmness, and controlled release of the drug over 24 hours.
- The new TCB-emulgel showed significantly improved anti-psoriatic effects in a mouse model, reducing psoriasis severity scores and inflammation markers compared to existing treatments, supporting its potential for clinical use in managing psoriasis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!